VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
2.870
-0.010 (-0.35%)
Dec 3, 2024, 10:05 AM EST - Market open
VYNE Therapeutics Revenue
VYNE Therapeutics had revenue of $121.00K in the quarter ending September 30, 2024, with 6.14% growth. This brings the company's revenue in the last twelve months to $493.00K, up 39.27% year-over-year. In the year 2023, VYNE Therapeutics had annual revenue of $424.00K, down -11.11%.
Revenue (ttm)
$493.00K
Revenue Growth
+39.27%
P/S Ratio
232.30
Revenue / Employee
$49,300
Employees
10
Market Cap
42.19M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 424.00K | -53.00K | -11.11% |
Dec 31, 2022 | 477.00K | -454.00K | -48.76% |
Dec 31, 2021 | 931.00K | -20.06M | -95.57% |
Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% |
Dec 31, 2019 | 443.00K | -3.15M | -87.68% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 996.89M |
FibroGen | 180.02M |
Celularity | 42.69M |
Accelerate Diagnostics | 11.91M |
LAVA Therapeutics | 7.40M |
Actinium Pharmaceuticals | 81.00K |
VYNE News
- 2 months ago - VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 - GlobeNewsWire
- 7 months ago - VYNE Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 9 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire